QSAR Studies on HIV-1 Protease Inhibitors Using Non-Linearly Transformed Descriptors

被引:7
|
作者
Saranya, Nallusamy [1 ]
Selvaraj, Samuel [1 ]
机构
[1] Bharathidasan Univ, Sch Life Sci, Dept Bioinformat, Tiruchirappalli 620024, India
关键词
HIV-1; protease; QSAR; binding affinity; descriptors; non-linear transformation; diverse inhibitors; regression; TSAR; IMMUNODEFICIENCY-VIRUS PROTEASE; ORALLY BIOAVAILABLE INHIBITOR; BIOLOGICAL EVALUATION; POTENT INHIBITOR; DESIGN; REGRESSION; MODELS;
D O I
10.2174/157340912799218534
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Human Immunodeficiency Virus (HIV)-1 protease is one of the key targets for Acquired Immunodeficiency Syndrome (AIDS). A large number of inhibitors are being designed for this target with the focus towards interactions with backbone atoms to combat drug resistance. In the present study, we have developed QSAR models for 99 inhibitors which include P-1/P-1' and P-2/P-2' substituents with diverse scaffolds. In the present work, HIV-1 protease inhibitors dataset with tanimoto similarity of 0.7 were compiled from The Binding Database (Binding DB). Multiple linear regression analysis was performed to compute the relationship between 2D and 3D structure descriptors and binding affinity. Untransformed and non-linearly transformed descriptors were used for the QSAR model development. Transformation of descriptors resulted in better QSAR model (r(2)=0.77) compared to the model developed using untransformed descriptors (r(2)=0.74). Molecular connectivity, cosmic bond angle energy and charged based descriptor were reported as a priori properties in the prediction of binding affinity. The developed models were validated using an external test set and r(test)(2) values of 0.73 and 0.72 were obtained. Models developed in this study have potential application in the prediction of binding affinity for the newly synthesized compounds.
引用
收藏
页码:10 / 49
页数:40
相关论文
共 50 条
  • [21] QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase
    Duchowicz, Pablo R.
    Fernandez, Michael
    Caballero, Julio
    Castro, Eduardo A.
    Fernandez, Francisco M.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (17) : 5876 - 5889
  • [22] Heterocyclic HIV-1 protease inhibitors
    Baures, PW
    [J]. ORGANIC LETTERS, 1999, 1 (02) : 249 - 252
  • [23] Novel HIV-1 protease inhibitors
    Lloyd, AW
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (12) : 533 - 534
  • [24] Adaptive inhibitors of the HIV-1 protease
    Ohtaka, H
    Freire, E
    [J]. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2005, 88 (02): : 193 - 208
  • [25] HIV-1 protease inhibitors in development
    Rusconi, S
    Catamancio, SL
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (03) : 387 - 395
  • [26] Dimerization inhibitors of HIV-1 protease
    Boggetto, N
    Reboud-Ravaux, M
    [J]. BIOLOGICAL CHEMISTRY, 2002, 383 (09) : 1321 - 1324
  • [27] Endothiopeptide inhibitors of HIV-1 protease
    Yao, S
    Zutshi, R
    Chmielewski, J
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (06) : 699 - 704
  • [28] HIV-1 protease inhibitors: A review
    Dietrich, MA
    Butts, JD
    Raasch, RH
    [J]. INFECTIONS IN MEDICINE, 1999, 16 (11) : 716 - +
  • [29] DIMERIZATION INHIBITORS OF HIV-1 PROTEASE
    CHMIELEWSKI, J
    FRANCISKOVICH, J
    WILSON, M
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1993, 206 : 138 - ORGN
  • [30] Lipopeptides as inhibitors of HIV-1 protease
    Schramm, HJ
    Büttner, J
    de Rosny, E
    Reboud-Ravaux, M
    Dick, A
    Schramm, W
    [J]. AIDS, 1998, 12 : S77 - S77